Previous 10 | Next 10 |
Image source: The Motley Fool. Arbutus Biopharma (NASDAQ: ABUS) Q1 2021 Earnings Call May 05, 2021 , 8:45 a.m. ET Operator Continue reading For further details see: Arbutus Biopharma (ABUS) Q1 2021 Earnings Call Transcript
Arbutus Biopharma Corporation (ABUS) Q1 2021 Earnings Conference Call May 05, 2021 08:45 AM ET Company Participants Pam Murphy - Investor Relations Bill Collier - President & Chief Executive Officer Dave Hastings - Chief Financial Officer Gaston Picchio - Chief Development Officer Mike So...
Arbutus Biopharma (ABUS) down 4% after reporting its first quarter 2021 financial results.The company reported Q1 revenue of $2.1M, up 41.6% from prior year but missed analyst expectations of $3.36M.Net loss widened to $19.6M or ($0.21) compared to loss of $16.8M or ($0.25) for Q1 2...
Arbutus Biopharma (ABUS): Q1 GAAP EPS of -$0.21 beats by $0.02.Revenue of $2.11M (+41.6% Y/Y) misses by $1.25M.Cash, cash equivalents and investments totaling $132.0 million as of March 31, 2021, as compared to $123.3 million as of December 31, 2020 and believes its sufficient to fund th...
AB-729, Arbutus’ proprietary subcutaneously delivered RNAi agent, continues to demonstrate robust and continuous declines in hepatitis B surface antigen (HBsAg) in subjects with chronic hepatitis B (HBV) with favorable safety and tolerability data Additional data from t...
Eupraxia Pharmaceuticals Inc. Announces Appointment of Bruce Cousins as President & CFO Eupraxia Pharmaceuticals Inc. Announces Appointment of Bruce Cousins as President & CFO Canada NewsWire VICTORIA, BC , May 3, 2021 /CNW/ - Eupraxia Pharmaceuti...
WARMINSTER, Pa., April 28, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on developing a cure for people with chronic hepatitis B virus (HBV) infection, as well as therapies to treat coronaviruses (includi...
Analysts Say Buy These Penny Stocks; Do You Agree? Many have taken an interest in penny stocks over the last year. By definition, this term refers to stocks that trade under $5. Inherently these stocks are very risky and volatile in nature. This can be a good thing or a bad thing, depen...
Arbutus Biopharma (ABUS), X-Chem and Proteros biostructures have entered into a research and license agreement focused on the discovery of novel inhibitors targeting the SARS-CoV-2 nsp5 main protease ((Mpro)).Arbutus shares were trading up more than 9% premarket.The agreement is des...
Sonoma Pharmaceuticals (SNOA) +28% on agreement with EMC pharma.Future FinTech Group (FTFT) +24% on acquiring bitcoin mining farm.AeroCentury (ACY) +22%.Jaguar Health (JAGX) +19% on FY results.P&F Industries (PFIN) +21%.AgEagle Aerial Systems (UAVS) +19% on FY results....
News, Short Squeeze, Breakout and More Instantly...
Arbutus Biopharma Corporation Company Name:
ABUS Stock Symbol:
NASDAQ Market:
Arbutus Biopharma Corporation Website:
WARMINSTER, Pa., July 18, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that it ...
Data highlighted in oral presentation at the European Association for the Study of the Liver (EASL) Congress WARMISTER, Pa., June 06, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmac...
In t he HBV003 trial, 67% of participants had HBsAg <10 IU/mL and 19% of participants had undetectable HBsAg when assessed for NUC discontinuation (end of treatment) or later, and 76% of participants were eligible for nucleos(t)ide analogue (NUC) therapy discontinuation. In the...